Ariad at ASGT
Ariad's GVHD data was included in a press release of studies showing 'significant progress in efforts to combat genetic disorders using gene therapies.'
The press release asgt.org
ASGT home page asgt.org
The abstract and link -
A New Humanized Fas Receptor-Based Suicide Strategy for the Induction of Controlled Graft-versus-tumor Effect after Allogeneic Marrow Transplantation.
Sarah Marktel, Daniel Thomis, Catia Traversari, Chiara Bonini, Zulma Magnani, Michael Gilman, C Bordignon, Tim Clackson
Telethon Institute for Gene Therapy (TIGET), Istituto Scientifico H.S.Raffaele, Milano, Italy; ARIAD Gene Therapeutics, Cambridge, MA
The abstract apnet.com
-------------------------
Ariad's other presentations -
1. Regulated Insulin Gene Delivery for Treatment of Type I Diabetes.
A Auricchio, GP Gao, P Zoltick, A Shifrin, S Raper, V Rivera, JM Wilson
Institute for Human Gene Therapy, The Wistar Institute, Depts. of Cellular and Molecular Engineering and Dept. of Surgery, University of Pennsylvania, Philadelphia, PA; Ariad Pharmaceuticals, Cambridge, MA
Abstract apnet.com
2. Regulated Feline Erythropoietin Expression with an Adeno-associated Viral Vector System in Cats.
Michael A. Schnell, Philip Zoltick, Tim Clackson, Vic Rivera, Gary Kurtzman, Urs Giger, James M. Wilson
Institute for Human Gene Therapy and Department of Molecular Cellular Engineering (School of Medicine), University of Pennsylvania; ARIAD Pharmaceuticals; Genovo, Inc.; Department of Clinical Studies (School of Veterinary Medicine), University of Pennsylvania, Philadelphia, Pennsylvania
Abstract apnet.com
3. Pharmacologic Regulated Expression in the Systemic Delivery of Erythropoietin Following Skeletal Muscle Transduction with rAAV Vectors in Non-Human Primates.
P. Zoltick, M. Schnell, N. Chirmule, G. Kurtzman, V. Rivera, T. Clackson, J. Wilson
Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania; ARIAD Gene Therapeutics Inc., Cambridge, Massachusetts
Abstract apnet.com
---------------------
Not sure what to make of this ongoing collaboration with Wilson. I'll comment soon on the data here...suffice to say, quite impressive progress. I need to check if the previous 'fail-safe' mechanism was humanized. If not, this is indeed 'new'...and sweet. |
